Cargando…

Portal Vein Tumor Thrombus: No Longer a Death Sentence

Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and a leading cause of cancer mortality worldwide. HCC commonly results from longstanding liver cirrhosis, which presents a host of complications and a severely diminished quality of life. Despite advancements in diagnosis, mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Esposito, Phillip, Matteo, Mika, Concepcion, Carissa, Montanarella, Matthew, Matteo, Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896835/
https://www.ncbi.nlm.nih.gov/pubmed/33628697
http://dx.doi.org/10.7759/cureus.12845
_version_ 1783653622001696768
author Esposito, Phillip
Matteo, Mika
Concepcion, Carissa
Montanarella, Matthew
Matteo, Jerry
author_facet Esposito, Phillip
Matteo, Mika
Concepcion, Carissa
Montanarella, Matthew
Matteo, Jerry
author_sort Esposito, Phillip
collection PubMed
description Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and a leading cause of cancer mortality worldwide. HCC commonly results from longstanding liver cirrhosis, which presents a host of complications and a severely diminished quality of life. Despite advancements in diagnosis, molecular pathogenesis, and management of the complications associated with irreversible liver diseases, HCC remains an aggressive malignancy with high mortality. HCC is often invasive to adjacent vasculature, including the inferior vena cava (IVC) and portal veins, which present with rapid morbidity and patient decline. This article describes a patient with cirrhosis and HCC previously treated with cryoablation now presenting with multiple new foci and invasion of the left medial portal vein. These lesions were synchronously cryoablated. Cryoablation is typically reserved for solid tumor masses within the soft tissue or specific organs. This report illustrates a technique of directly cryoablating tumors within vessels. We achieved adequate cryoablation of the intravascular HCC portal vein tumor thrombus in the left medial portal vein. A one-month follow-up CT scan demonstrated significant portal vein macrovascular invasion (MVI) regression from 22.8 mm to 7.7 mm. Portal vein invasion by HCC presents unique challenges and traditionally precludes percutaneous or surgical therapy. Our technique shows successful cryoablation of MVI as a viable adjunct to treatment in select patients.
format Online
Article
Text
id pubmed-7896835
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-78968352021-02-23 Portal Vein Tumor Thrombus: No Longer a Death Sentence Esposito, Phillip Matteo, Mika Concepcion, Carissa Montanarella, Matthew Matteo, Jerry Cureus Radiology Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and a leading cause of cancer mortality worldwide. HCC commonly results from longstanding liver cirrhosis, which presents a host of complications and a severely diminished quality of life. Despite advancements in diagnosis, molecular pathogenesis, and management of the complications associated with irreversible liver diseases, HCC remains an aggressive malignancy with high mortality. HCC is often invasive to adjacent vasculature, including the inferior vena cava (IVC) and portal veins, which present with rapid morbidity and patient decline. This article describes a patient with cirrhosis and HCC previously treated with cryoablation now presenting with multiple new foci and invasion of the left medial portal vein. These lesions were synchronously cryoablated. Cryoablation is typically reserved for solid tumor masses within the soft tissue or specific organs. This report illustrates a technique of directly cryoablating tumors within vessels. We achieved adequate cryoablation of the intravascular HCC portal vein tumor thrombus in the left medial portal vein. A one-month follow-up CT scan demonstrated significant portal vein macrovascular invasion (MVI) regression from 22.8 mm to 7.7 mm. Portal vein invasion by HCC presents unique challenges and traditionally precludes percutaneous or surgical therapy. Our technique shows successful cryoablation of MVI as a viable adjunct to treatment in select patients. Cureus 2021-01-21 /pmc/articles/PMC7896835/ /pubmed/33628697 http://dx.doi.org/10.7759/cureus.12845 Text en Copyright © 2021, Esposito et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Radiology
Esposito, Phillip
Matteo, Mika
Concepcion, Carissa
Montanarella, Matthew
Matteo, Jerry
Portal Vein Tumor Thrombus: No Longer a Death Sentence
title Portal Vein Tumor Thrombus: No Longer a Death Sentence
title_full Portal Vein Tumor Thrombus: No Longer a Death Sentence
title_fullStr Portal Vein Tumor Thrombus: No Longer a Death Sentence
title_full_unstemmed Portal Vein Tumor Thrombus: No Longer a Death Sentence
title_short Portal Vein Tumor Thrombus: No Longer a Death Sentence
title_sort portal vein tumor thrombus: no longer a death sentence
topic Radiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896835/
https://www.ncbi.nlm.nih.gov/pubmed/33628697
http://dx.doi.org/10.7759/cureus.12845
work_keys_str_mv AT espositophillip portalveintumorthrombusnolongeradeathsentence
AT matteomika portalveintumorthrombusnolongeradeathsentence
AT concepcioncarissa portalveintumorthrombusnolongeradeathsentence
AT montanarellamatthew portalveintumorthrombusnolongeradeathsentence
AT matteojerry portalveintumorthrombusnolongeradeathsentence